Pharmaceutical manufacturers have overcome the logistics problems that arose at the beginning of the COVID-19 pandemic and the shortage of certain active pharmaceutical ingredients (APIs), said President of the Association of Manufacturers of Medications of Ukraine (AMMU) Petro Bahriy.
“Among the general problems that have arisen with the introduction of quarantine [at the beginning of the epidemic], I would single out the problems of logistics, difficulties with the import, transportation of pharmaceutical products and their registration in connection with closed borders, as well as problems with the so-called ‘anticovid’ goods, for which there is an increased demand today,” he said in an exclusive interview with Interfax-Ukraine.
Bahriy noted that the price of some APIs of drugs used in the treatment of COVID-19 and complications of this disease has grown significantly in the global market – there are problems with production due to delays in deliveries.
“This is not a critical situation for the industry as a whole. We have to restructure, place orders earlier, realizing that delivery times will be longer than they were before the pandemic. For the entire time of the pandemic, consumers have not particularly felt a shortage of medicines,” he said.
APIS, BAHRIY, COVID-19, PANDEMIC, PHARMA, SHORTAGES
Related:
